Huiyun Liu

TL;DR: A gradient model of oncogenic NRAS signaling in which the output is gated, resulting in the decoupling of discrete downstream biological phenotypes as a result of incomplete inhibition is suggested, offering a new framework to identify nonobvious coextinction target(s) for combined pharmacological inhibition in NRAS-mutant melanomas.

TL;DR: It is demonstrated that large studies of acute leukemia PDXs that mimic human randomized clinical trials can characterize drug efficacy and generate transcriptional, functional, and proteomic biomarkers in both treatment-naive and relapsed/refractory disease.

TL;DR: It is shown that germline triplication of only 31 genes orthologous to human chromosome 21q22 confers mouse progenitor B cell self renewal in vitro, maturation defects in vivo and B-ALL with either the BCR-ABL fusion protein or CRLF2 with activated JAK2.

TL;DR: CHZ868 potently suppressed the growth of CRLF2-rearranged human B-all cells, abrogated JAK2 signaling, and improved survival in mice with human or murine B-ALL, and these data support the testing of type II Jak2 inhibition in patients with JAK1-dependent leukemias and other disorders.

TL;DR: In this article, the single-cell mass accumulation rate (MAR) was used to predict drug response using samples as small as 25 μl of peripheral blood while maintaining cell viability and compatibility with downstream characterization.